According to a new study published in the journal Annals of Oncology, researchers in Germany have found that neoadjuvant treatment with anthracycline-taxane-based chemotherapy or treatment with everolimus plus paclitaxel in patients with triple negative breast cancer is not effective.
Early results of the GeparQuinto study demonstrated that neoadjuvant anthracycline-taxed based chemotherapy with bevacizumab increased pathological complete response rates in patients with triple negative breast cancer. The study also showed that patients who were non-responders to that regimen who then received everolimus plus paclitaxel had no difference in pathological complete response compared with those that received paclitaxel alone.
The long-term results show a 3-year disease-free survival rate of 80.8% and a 3-year overall survival rate of 89.7% in both groups of patients with breast cancer that received epirubin, cyclophosphamide, and docetaxel with or without bevacizumab. In addition, there was no difference in disease-free survival or overall survival rates between early non-responders that received paclitaxel with or without everolimus.
Although early results demonstrated increased pathological complete response rates in patients with breast cancer, particularly triple negative breast cancer, these long-term results to do not support the use of adding bevacizumab or everolimus.
The authors present disease–free (DFS) and overall survival (OS) analyses. Long–term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline/taxane–based chemotherapy or everolimus in addition to paclitaxel for non–early responding patients.